GRAL GRAIL, LLC
Company Analysis
Latest News
🟢 GRAIL is trading 4.1% up today amid a broader market rebound and risk-on sentiment
GRAIL is trading at $71.34 (4.1% up), rebounding from last week’s biotech volatility and Friday’s sector-wide selloff. • The advance aligns with a broader...
🔴 GRAIL is trading 4.7% down today amid a broader biotech selloff and reversal of yesterday's rally
GRAIL is trading 4.7% down at $67.77 today, reversing a portion of yesterday's gains as the broader biotech sector faces selling pressure. • The decline...
🟢 GRAIL is trading 10.6% up today amid tech rebound and cooling inflation
GRAIL is trading 10.6% up now at $70.19 amid a strong rebound in technology stocks driven by cooling inflation data and robust Microsoft earnings. • Broader...
🟢 GRAIL is trading 7.7% up today amid a broader tech rebound and cooling inflation
GRAIL is trading 7.7% up now at $68.33 as part of a broader rebound in technology shares driven by cooling inflation and strong Microsoft earnings. • The...
🔴 GRAIL falls 4.2% — Biotech Stocks Decline on Broad Market Weakness
With Biotech (XBI) down 2.2%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector, as measured by the XBI ETF,...
🔴 GRAIL is trading 4.1% down today amid broader biotech caution and tariff uncertainty
GRAIL is trading 4.1% down at $67.50 today, appearing to move in line with cautious sentiment toward high-cost biotech and diagnostics plays rather than a...
GRAIL Sued for Fraud, Following 50% Crash Over NHS-Galleri Trial
Multiple law firms filed a securities fraud class-action lawsuit against GRAIL, Inc. and its executives. The legal action alleges the company made misleading...
🟢 GRAIL is trading 4.3% up today as it rebounds from recent losses
GRAIL is trading at $71.88 (4.3% up) as the stock rebounds from recent losses despite a lack of company-specific catalysts. • The upward move follows a 5.11%...
🔴 GRAIL is trading 4.8% down today despite no clear company-specific catalyst
GRAIL is trading -4.82% lower at $69.12 today, as the stock faces downward pressure despite a lack of fresh company announcements or earnings results. • The...
🔴 GRAIL is trading 4.1% down today amid trial failure fallout and short-seller pressure
GRAIL is trading 4.1% down at $71.32 as investors remain cautious following the recent NHS-Galleri trial failure and a critical short-seller report. • The...
🔴 GRAIL is trading 4.1% down today on securities-fraud class action reminders
GRAIL is trading 4.1% down at $72.71 following fresh securities-fraud class action reminders tied to the company's failed NHS-Galleri cancer trial in...
🟢 GRAIL is trading 5.5% up today as class-action deadlines loom following February trial failure
GRAIL is trading 5.5% up today at $73.99, attempting to recover from steep losses tied to a failed NHS-Galleri cancer trial and subsequent allegations of...
GRAIL faces fraud lawsuits, following failed NHS-Galleri cancer trial results
Law firms Bleichmar Fonti & Auld LLP and Bronstein, Gewirtz & Grossman, LLC filed a class-action lawsuit against GRAIL, Inc. The suit alleges GRAIL and its...
🔴 GRAL is trading 4.7% down today on fresh coverage of securities fraud litigation over Galleri trial disclosures
GRAL is trading 4.7% down at $65.72 following fresh coverage of a securities fraud class action lawsuit tied to its NHS-Galleri trial disclosures. • The...
🟢 GRAL is trading 4.3% up today with no clear stock-specific catalyst yet
GRAL is trading 4.3% up now at $71.05, rebounding from recent consolidation around the high‑$60s. No fresh company-specific news, filings, or major analyst...